Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease (SPARK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03318523
Recruitment Status : Recruiting
First Posted : October 24, 2017
Last Update Posted : May 22, 2018
Information provided by (Responsible Party):

Brief Summary:
To evaluate the dose-related safety of BIIB054, to evaluate the pharmacodynamic effects of BIIB054 on the integrity of nigrostriatal dopaminergic nerve terminals, to assess the pharmacokinetic (PK) profile of BIIB054 and to evaluate the immunogenicity of BIIB054.

Condition or disease Intervention/treatment Phase
Parkinson's Disease Drug: Placebo Drug: BIIB054 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 311 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease
Actual Study Start Date : December 6, 2017
Estimated Primary Completion Date : April 30, 2021
Estimated Study Completion Date : June 30, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Placebo

Year 1: Participants will receive matching placebo to BIIB054 on Day 1 and then every 4 weeks.

Year 2: Participants who received placebo in year 1 will be randomized into one of the active treatment arms in year 2 and will receive BIIB054 intravenous (IV) infusion on Week 52 and then every 4 weeks.

Drug: Placebo
Administered as specified in the treatment arm

Experimental: BIIB054 250 mg
Participants will receive BIIB054 250 mg intravenous (IV) infusion on Day 1 and then every 4 weeks.
Drug: BIIB054
Administered as specified in the treatment arm.

Experimental: BIIB054 1250 mg
Participants will receive BIIB054 1250 mg IV infusion on Day 1 and then every 4 weeks.
Drug: BIIB054
Administered as specified in the treatment arm.

Experimental: BIIB054 3500 mg
Participants will receive BIIB054 3500 mg IV infusion on Day 1 and then every 4 weeks.
Drug: BIIB054
Administered as specified in the treatment arm.

Primary Outcome Measures :
  1. Percentage of Participants With Adverse Event (AEs) and Serious Adverse Event (SAEs) [ Time Frame: Up to Week 52 ]
    An AE is any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose results in death, requires inpatient hospitalization, results in persistent or significant disability and/or results in a congenital anomaly.

  2. Change From Baseline in Clinical Laboratory Test Data [ Time Frame: Baseline, Week 52 ]
  3. Change From Baseline in Vital Sign Measurements [ Time Frame: Baseline, Week 52 ]
  4. Change From Baseline in Neurological and Physical Examination Findings [ Time Frame: Baseline, Week 52 ]
  5. Change From Baseline in Electrocardiograms (ECGs) [ Time Frame: Baseline, Week 52 ]
  6. Change From Baseline in Brain Magnetic Resonance Imaging (MRI) [ Time Frame: Baseline, Week 52 ]

Secondary Outcome Measures :
  1. Change in Striatal Binding Ratio (SBR) in Putamen, Striatum, and Caudate as Measured by Striatal-Photon Emission Computed Tomography (SPECT) Imaging of the Dopamine Transporter With Ioflupane I123 (DaTscan™) [ Time Frame: Baseline, Week 52 ]
  2. Concentration of BIIB054 in the Serum [ Time Frame: Baseline and at multiple time points (up to 2 years) ]
  3. Percentage of Participants With Anti-BIIB054 Antibodies in the Serum [ Time Frame: Baseline and at multiple time points (up to 2 years) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Diagnosed with Parkinson's disease (PD) within a maximum of 3 years prior to Screening.
  • Score of ≤2.5 on the Modified Hoehn and Yahr Scale.
  • Has not received levodopa or any other treatment for PD (dopamine agonists, amantadine, anticholinergics, MAO-B inhibitors, or safinamide) for at least 12 weeks prior to Day 1 and, in the opinion of the Investigator, is not expected to require PD treatment for at least 6 months following Day 1. Maximum total duration of prior PD regimens should not exceed 30 days.
  • Screening dopamine transporter (DaT)/ single-photon emission computed tomography (SPECT) results consistent with neurodegenerative Parkinsonism (central reading).
  • All women of childbearing potential and all men must practice highly effective contraception during the study and for 6 months after their last dose of study treatment.

Exclusion Criteria:

  • Presence of freezing of gait.
  • MOCA score <23 or other significant cognitive impairment or clinical dementia that, in the opinion of the Investigator, would interfere with study evaluation.
  • History of or screening brain magnetic resonance imaging (MRI) scan indicative of clinically significant abnormality, as read by central reader.
  • History of severe allergic or anaphylactic reactions, or history of hypersensitivity to BIIB054 or any of the inactive ingredients in the drug product or to radioligands or iodine used in the study.
  • Participation in any active immunotherapy study targeting alpha-synuclein.
  • Use of allowed medications not previously specified at doses that have not been stable for at least 8 weeks before Day 1, and/or that are not expected to remain stable for the duration of the study.
  • Clinically significant abnormal laboratory test values at Screening, as determined by the Investigator.
  • Blood donation (1 unit or more) within 8 weeks before Day 1 (must also refrain from donating blood for the duration of the study).

NOTE : Other protocol defined Inclusion/Exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03318523

Contact: US Biogen Medical Information 866-633-4636

United States, Alabama
University of Alabama at Birmingham Recruiting
Birmingham, Alabama, United States, 35233
Contact: Jenna Smith    205-996-2807      
Principal Investigator: Natividad Stover         
United States, Arizona
St. Joseph's Hopsital & Medical Center- Barrow Neurological Institute Active, not recruiting
Phoenix, Arizona, United States, 85013
Banner Sun Health Research Institute Active, not recruiting
Sun City, Arizona, United States, 85351
United States, California
Research Site Active, not recruiting
San Francisco, California, United States, 94158
United States, Colorado
Research Site Recruiting
Aurora, Colorado, United States, 80045
United States, Florida
Research Site Recruiting
Boca Raton, Florida, United States, 33486
Research Site Recruiting
Orlando, Florida, United States, 32806
Research Site Recruiting
Tampa, Florida, United States, 33616
United States, Illinois
Research Site Recruiting
Chicago, Illinois, United States, 60611
United States, Louisiana
Ochsner Health System Recruiting
New Orleans, Louisiana, United States, 70121
Contact: Ashley LaRoche    504-703-0755   
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Hans Erickson   
Research Site Active, not recruiting
Boston, Massachusetts, United States, 02118
United States, Michigan
Quest Research Institute Recruiting
Farmington Hills, Michigan, United States, 48334
Contact: Renee    248-957-8940   
Principal Investigator: Aaron L Ellenbogen, DO, MPH         
United States, North Carolina
Research Site Recruiting
Durham, North Carolina, United States, 27705
Wake Forest Baptist Health Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Jessica Dimos    336-716-8694   
United States, Ohio
Research Site Recruiting
Cleveland, Ohio, United States, 44106
United States, Washington
Research Site Recruiting
Kirkland, Washington, United States, 98034
Research Site Recruiting
Spokane, Washington, United States, 99204
Sponsors and Collaborators
Study Director: Medical Director Biogen

Additional Information:
Responsible Party: Biogen Identifier: NCT03318523     History of Changes
Other Study ID Numbers: 228PD201
2016-0044610-95 ( Other Identifier: European Medicines Agency (EudraCT) )
First Posted: October 24, 2017    Key Record Dates
Last Update Posted: May 22, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Biogen:
Parkinson's Disease
Alpha synuclein

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases